VTGN · Categories · Form 4

VTGN - SEC Form 4 insider transactions

Vistagen Therapeutics Inc. (VTGN) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for VTGN

• 15d
  SEC Form 4 filed by Chief Medical Officer Angelov Angel S

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 54d
  SEC Form 4 filed by Tressler Nick B.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 54d
  SEC Form 4 filed by Singh Shawn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 54d
  SEC Form 4 filed by Prince Joshua S.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 54d
  SEC Form 4 filed by Cote Elissa S.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 54d
  SEC Form 4 filed by Adler Reid G.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 148d
  Chief Operating Officer Prince Joshua S. was granted 4,386 shares, increasing direct ownership by 40% to 15,249 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 181d
  SEC Form 4 filed by Chief Financial Officer Tressler Nick B.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 211d
  SEC Form 4 filed by Director Edick Paul R

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 265d
  SEC Form 4 filed by Director Saxe Jon S

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 265d
  SEC Form 4 filed by Director Rotunno Mary L.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 265d
  SEC Form 4 filed by Director Fitzpatrick Margaret M

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 265d
  SEC Form 4 filed by Director Curley Joanne

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 265d
  SEC Form 4 filed by Director Cunningham Ann Michelle

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 337d
  Chief Operating Officer Prince Joshua S. was granted 4,882 shares, increasing direct ownership by 82% to 10,863 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 337d
  Chief Legal Officer Adler Reid G. was granted 7,541 shares, increasing direct ownership by 46% to 24,050 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 337d
  CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 6,617 shares, increasing direct ownership by 107% to 12,801 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 337d
  President and CEO Singh Shawn was granted 7,541 shares, increasing direct ownership by 72% to 18,028 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 4 filed by Chief Corp Development Officer Cote Elissa S.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 4 filed by CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 4 filed by Chief Legal Officer Adler Reid G.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 4 filed by Chief Operating Officer Prince Joshua S.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 343d
  SEC Form 4 filed by President and CEO Singh Shawn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 506d
  Chief Operating Officer Prince Joshua S. was granted 3,310 shares, increasing direct ownership by 124% to 5,981 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 506d
  CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 2,592 shares, increasing direct ownership by 72% to 6,184 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Cunningham Ann Michelle

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Curley Joanne

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Gin Jerry B

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Saxe Jon S

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Fitzpatrick Margaret M

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 631d
  SEC Form 4 filed by Director Rotunno Mary L.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 701d
  Chief Operating Officer Prince Joshua S. was granted 2,671 shares (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 701d
  CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn was granted 3,592 shares (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 701d
  CHF CORP DEVEL OFF, GEN COUNS Adler Reid G. was granted 4,854 shares, increasing direct ownership by 42% to 16,509 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 701d
  CHIEF EXECUTIVE OFFICER Singh Shawn was granted 4,854 shares, increasing direct ownership by 86% to 10,487 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 706d
  SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Singh Shawn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 706d
  SEC Form 4 filed by CHF CORP DEVEL OFF, GEN COUNS Adler Reid G.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 706d
  SEC Form 4 filed by CHIEF FINANCIAL OFFICER Anderson Cynthia Lynn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 706d
  SEC Form 4 filed by Chief Operating Officer Prince Joshua S.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 819d
  SEC Form 4 filed by Rotunno Mary L.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 819d
  SEC Form 4 filed by Saxe Jon S

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 819d
  SEC Form 4 filed by Cunningham Ann Michelle

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 819d
  SEC Form 4 filed by Curley Joanne

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 819d
  SEC Form 4 filed by Fitzpatrick Margaret M

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 819d
  SEC Form 4 filed by Gin Jerry B

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 882d
  Adler Reid G. was granted 167 shares, increasing direct ownership by 1% to 11,655 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 882d
  Singh Shawn was granted 167 shares, increasing direct ownership by 3% to 5,633 units (SEC Form 4)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 971d
  SEC Form 4 filed by Commodore Capital Lp

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1015d
  SEC Form 4 filed by Anderson Cynthia Lynn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1029d
  SEC Form 4: Commodore Capital Lp bought $17,961,079 worth of shares (775,756 units at $23.15)

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1064d
  SEC Form 4 filed by Singh Shawn

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1064d
  SEC Form 4 filed by Dotson Jerrold Duane

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1064d
  SEC Form 4 filed by Adler Reid G.

  4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
• 1247d
  SEC Form 4: Dotson Jerrold Duane was granted 5,000 shares, increasing direct ownership by 5% to 105,111 units

  4 - VistaGen Therapeutics, Inc. (0001411685) (Issuer)
• 1247d
  SEC Form 4: Singh Shawn was granted 5,000 shares, increasing direct ownership by 3% to 158,998 units

  4 - VistaGen Therapeutics, Inc. (0001411685) (Issuer)
• 1381d
  SEC Form 4: Gin Jerry B bought $35,740 worth of shares (200,000 units at $0.18)

  4 - VistaGen Therapeutics, Inc. (0001411685) (Issuer)
• 1384d
  SEC Form 4: Adler Reid G. bought $50,910 worth of shares (300,000 units at $0.17), increasing direct ownership by 866% to 334,629 units

  4 - VistaGen Therapeutics, Inc. (0001411685) (Issuer)
• 1385d
  SEC Form 4: Singh Shawn bought $103,200 worth of shares (600,000 units at $0.17)

  4 - VistaGen Therapeutics, Inc. (0001411685) (Issuer)
• 1419d
  SEC Form 4: Dotson Jerrold Duane was granted 5,000 shares, increasing direct ownership by 5% to 100,111 units

  4 - VistaGen Therapeutics, Inc. (0001411685) (Issuer)
• 1419d
  SEC Form 4: Singh Shawn was granted 5,000 shares, increasing direct ownership by 3% to 153,998 units

  4 - VistaGen Therapeutics, Inc. (0001411685) (Issuer)

Other VTGN categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends